Search the web
Welcome, Guest
[Sign Out, My Account]
EDGAR_Online

Quotes & Info
Enter Symbol(s):
e.g. YHOO, ^DJI
Symbol Lookup | Financial Search
AVNR > SEC Filings for AVNR > Form 8-K on 15-Nov-2013All Recent SEC Filings

Show all filings for AVANIR PHARMACEUTICALS, INC. | Request a Trial to NEW EDGAR Online Pro

Form 8-K for AVANIR PHARMACEUTICALS, INC.


15-Nov-2013

Entry into a Material Definitive Agreement, Termination of a Materia


Item 1.01. Entry into a Material Definitive Agreement.

On November 15, 2013, Avanir Pharmaceuticals, Inc. (the "Company") and American Stock Transfer & Trust Company, LLC (the "Rights Agent") entered into an Amendment and Termination of Stockholder Rights Agreement (the "Amendment") with respect to the Stockholder Rights Agreement dated as of March 20, 2009 by and between the Company and the Rights Agent (the "Rights Agreement") (i.e., its poison pill), which terminated the Company's poison pill.

The Amendment changes the definition of "Final Expiration Date" in the Rights Agreement from March 20, 2019 to November 15, 2013, such that, as of 5:00 p.m. New York time on November 15, 2013, the rights to purchase Series A Junior Participating Cumulative Preferred Stock (the "Series A Preferred Stock") issued pursuant to the Rights Agreement (the "Rights") expired and are no longer outstanding and the Rights Agreement terminated. The foregoing summary of the Amendment is qualified in its entirety by reference to the full text of the Amendment, which is set forth as Exhibit 4.1 to this Current Report on Form 8-K and incorporated herein by reference.

The Rights Agreement is described in the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission on March 25, 2009, and such description is incorporated herein by reference.



Item 1.02. Termination of a Material Definitive Agreement.

The information contained in Item 1.01 above is incorporated by reference into this item 1.02.



Item 3.03 Material Modification to Rights of Security Holders.

The information contained in Item 1.01 above is incorporated by reference into this item 3.03.

After the expiration of the Rights and termination of the Rights Agreement, on November 15, 2013 the Company filed with the Delaware Secretary of State a Certificate of Elimination relating to the certificate of designation of the Series A Preferred Stock (the "Certificate of Elimination"), which has the effect of returning the authorized shares that were previously designated as Series A Preferred Stock to the status of authorized but unissued shares of the preferred stock of the Company, without designation as to series or rights, preferences, privileges or limitations. The foregoing summary of the Certificate of Elimination is qualified in its entirety by reference to the full text of the Certificate of Elimination, which is set forth as Exhibit 3.1 to this Current Report on Form 8-K and incorporated herein by reference.



Item 5.02. Departure of Directors or Certain Officers; Election of Directors;
Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On November 11, 2013, the Compensation Committee of the Board of Directors of the Company approved (i) annual increases in the base salaries of those officers identified below and (ii) the payment of annual cash bonus awards for fiscal 2013 for the same officers. Salary increases were effective as of October 1, 2013, which was the start of the current fiscal year. Bonuses were awarded based on individual and overall Company performance in fiscal 2013.

Name                                  Title                    New Salary        Bonus Payment
Keith A. Katkin        President and Chief Executive
                       Officer                                $    611,773      $       318,330
Rohan Palekar          Senior Vice President, Chief
                       Commercial Officer                     $    392,697      $       175,655
Joao Siffert, M.D.     Senior Vice President, R&D & Chief
                       Scientific Officer                     $    382,071      $       174,026
Christine G. Ocampo    Vice President, Finance                $    268,425      $        89,296

-2-


The following table shows the base salaries for those officers for fiscal 2014, after giving effect to salary increases effective as of October 1, 2013, as well as the average salaries in the Company's peer group at the 25th, 50th and 75th percentiles.

                                                                                    Base Salary - Market Data(1)
                                                          Fiscal 2013          25th             50th             75th
Name                               Title                  Base Salary       Percentile       Percentile       Percentile
Keith A. Katkin       President and Chief Executive
                      Officer                            $     611,773     $    544,300     $    611,400     $    707,600
Rohan Palekar         Senior Vice President, Chief
                      Commercial Officer                 $     392,697     $    345,200     $    358,000     $    374,200
Joao Siffert, M.D.    Senior Vice President, R&D &
                      Chief Scientific Officer           $     382,071     $    375,000     $    382,300     $    414,100
Christine G. Ocampo   Vice President, Finance            $     268,425     $    245,600     $    261,900     $    286,400

(1) Source: Radford, a division of AON, Executive Compensation Review of August 2013, subject to a 3.2% increase for fiscal 2014.

The target bonuses as a percentage of base salary for those officers for fiscal 2013 are set forth in the following table:

                                                                                                             Target Annual Incentive Bonus
                                                                                                                   - Market Data (1)
                                                                              Target Bonus
                                                                               (% of Base            25th                 50th                 75th
Name                                          Title                              Salary)          Percentile           Percentile           Percentile
Keith A. Katkin       President and Chief Executive Officer                              50 %              55 %                 65 %                 75 %
Rohan Palekar         Senior Vice President, Chief Commercial Officer                    40 %              40 %                 40 %                 45 %
Joao Siffert, M.D.    Senior Vice President, R&D & Chief Scientific Officer              40 %              40 %                 40 %                 50 %
Christine G. Ocampo   Vice President, Finance                                            30 %              30 %                 30 %                 40 %

(1) Source: Radford, a division of AON, Executive Compensation Review of August 2013.



Item 5.03. Amendments to Articles of Incorporation or Bylaws; Change of Fiscal Year.

The information contained in the second paragraph of Item 3.03 above is incorporated by reference into this Item 5.03.



Item 8.01. Other Events.

On November 11, 2013, the Compensation Committee recommended, and the Board of Directors approved, an increase in the number of shares reserved for issuance under the Company's 2005 Equity Incentive Plan (the "Plan") pursuant to the Plan's evergreen provision. Under the Plan, the Board of Directors approved an increase of 325,000 shares for fiscal 2014.



Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.       Description

3.1               Certificate of Elimination of Series A Junior Participating
                  Cumulative Preferred Stock, dated November 15, 2013

-3-



4.1 Amendment and Termination of Stockholder Rights Agreement, dated November 15, 2013, by and between Avanir Pharmaceuticals, Inc. and American Stock Transfer & Trust Company, LLC.

* * *

-4-


  Add AVNR to Portfolio     Set Alert         Email to a Friend  
Get SEC Filings for Another Symbol: Symbol Lookup
Quotes & Info for AVNR - All Recent SEC Filings
Sign Up for a Free Trial to the NEW EDGAR Online Pro
Detailed SEC, Financial, Ownership and Offering Data on over 12,000 U.S. Public Companies.
Actionable and easy-to-use with searching, alerting, downloading and more.
Request a Trial      Sign Up Now


Copyright © 2014 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service
SEC Filing data and information provided by EDGAR Online, Inc. (1-800-416-6651). All information provided "as is" for informational purposes only, not intended for trading purposes or advice. Neither Yahoo! nor any of independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. By accessing the Yahoo! site, you agree not to redistribute the information found therein.